Column Capital Advisors’s West Pharmaceutical WST Stock Holding History

Column Capital Advisors’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-22	Closed	-$4K	–	880
2020 Q2	$4K	Buy	+22	New	+$4.32K	﹤0.01%	610

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Column Capital Advisors's WST Position: Q3 2020 in Review

Column Capital Advisors sold out of West Pharmaceutical (WST) in Q3 2020, closing a stake of 22 shares — an estimated $4K sold.

Column Capital Advisors first reported a position in WST in Q2 2020 and held it in 1 quarter. The position peaked at $4K in Q2 2020. 573 funds tracked by Wall St. Rank hold WST as of Q3 2020.

Column Capital Advisors reported no remaining West Pharmaceutical position as of Q3 2020 after selling out during the quarter.
Column Capital Advisors sold 22 West Pharmaceutical shares in Q3 2020, an estimated $4K.
Column Capital Advisors first reported a position in West Pharmaceutical in Q2 2020 and held it in 1 quarter.
Column Capital Advisors's West Pharmaceutical position peaked at $4K in Q2 2020.
573 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2020.

Based on Column Capital Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.